Replies to post #578596 on NorthWest Biotherapeutics Inc (NWBO)

[NotSure2]

Same here, but it is all good. What is going to hurt this stock, is all the over positive unrealistic viral things like:

"They are going to get MHRA aproval by August this year"

(meanwhile, realisticaly, they will only be able to apply by ~ May June if we are lucky, meaning MHRA aproval end of 2023 to mid 2024). Oh yeah, what about FDA? Well then it is earliest end 2024, more likely mid 2025 (if everything goes well). But hopefully they concentrate on UK... Once they can get a positive revenue... Then its all in the bag (mainly, always have risk, will this patent enough to cover this and thaylt etc...) Will see, hoping for the best.

People dont seem to read the annual report... Or dismiss some important information in them...

[norisknorewards]

I disagree, baked in the cake would imply it's been priced in already, the last few weeks trading suggests this PR has been anything but already priced in.

[dstock07734]

You cannot be serious. For you, the approval might be expected for a long time. Not for new investors and potential institutional investors which might have been watching and wondering if an OTC company can get done this mission impossible. As PR mentioned, there are only three approved cell therapies. Two were approved lately and DCVax-L is one of the two. Every investor who has common sense knows what is going to happen next. This news combined with Dr. Bosch presentation will certainly have significant impact on sp.

[biosectinvestor]

Was expected by longs but shorts made a considerable effort to convince the market and new investors that it might never happen and if it did it would be a long time coming, which was likely one reason for recent sell offs.

So no, it’s not baked in. Plus it is a very positive sign from a primary/highly regarded regulator and the regulator in the world that is most likely to be very much in sync with the FDA.

Very positive sign when all the bears have been saying not going to happen. Additionally, that plus the continued allowance of sale of DCVax-L to UK citizens based in highly successful trial results. It bodes well for approval and not well for the bear case.